Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen Mangar

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Molecules (Basel, Switzerland)|December 23, 2023
Bench to Bedside Development of [<sup>18</sup>F]Fluoromethyl-(1,2-<sup>2</sup>H<sub>4</sub>)choline ([<sup>18</sup>F]D4-FCH)Amarnath Challapalli, Tara D Barwick, Suraiya R Dubash, et al.
Contemporary Clinical Trials|March 18, 2023
Healthcare systems data in the context of clinical trials - A comparison of cardiovascular data from a clinical trial dataset with routinely collected dataArchie Macnair, Matthew Nankivell, Macey L Murray, et al.
BMJ Open|November 19, 2021
Metastatic prostate cancer men's attitudes towards treatment of the local tumour and metastasis evaluative research (IP5-MATTER): protocol for a prospective, multicentre discrete choice experiment studyMartin John Connor, Mesfin G Genie, Michael Gonzalez, et al.
Journal of Medical Economics|September 1, 2023
Focal therapy versus radical prostatectomy and external beam radiotherapy as primary treatment options for non-metastatic prostate cancer: results of a cost-effectiveness analysisDeepika Reddy, Marieke van Son, Max Peters, et al.
European Urology Oncology|July 7, 2024
Patients' Preferences for Cytoreductive Treatments in Newly Diagnosed Metastatic Prostate Cancer: The IP5-MATTER StudyMartin J Connor, Mesfin Genie, Tim Dudderidge, et al.
European Urology Oncology|June 14, 2025
Combination Cytoreductive Surgery, Radiotherapy, or Ablation for De Novo Metastatic Prostate Cancer: The IP2-ATLANTA Internal Pilot, Phase 2, Randomised Controlled TrialMartin J Connor, Taimur T Shah, Johanna Sukumar, et al.
Prostate Cancer and Prostatic Diseases|May 2, 2021
Conventional radical versus focal treatment for localised prostate cancer: a propensity score weighted comparison of 6-year tumour controlMarieke J van Son, Max Peters, Deepika Reddy, et al.
Contemporary Clinical Trials|April 16, 2026
The Imperial Prostate 9 - Approaches To Long-term Active Surveillance: Regular MRI scans versus standard of care (IP9-ATLAS) randomised controlled trialArchana Gopalakrishnan, Alexander Light, Nikhil Mayor, et al.
Lancet (London, England)|February 14, 2021
Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programmeRuth E Langley, Duncan C Gilbert, Trinh Duong, et al.
BMJ Open|February 26, 2021
Additional Treatments to the Local tumour for metastatic prostate cancer-Assessment of Novel Treatment Algorithms (IP2-ATLANTA): protocol for a multicentre, phase II randomised controlled trialMartin John Connor, Taimur Tariq Shah, Katarzyna Smigielska, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Molecules (Basel, Switzerland)|December 23, 2023
Bench to Bedside Development of [<sup>18</sup>F]Fluoromethyl-(1,2-<sup>2</sup>H<sub>4</sub>)choline ([<sup>18</sup>F]D4-FCH)Amarnath Challapalli, Tara D Barwick, Suraiya R Dubash, et al.
Contemporary Clinical Trials|March 18, 2023
Healthcare systems data in the context of clinical trials - A comparison of cardiovascular data from a clinical trial dataset with routinely collected dataArchie Macnair, Matthew Nankivell, Macey L Murray, et al.
BMJ Open|November 19, 2021
Metastatic prostate cancer men's attitudes towards treatment of the local tumour and metastasis evaluative research (IP5-MATTER): protocol for a prospective, multicentre discrete choice experiment studyMartin John Connor, Mesfin G Genie, Michael Gonzalez, et al.
Journal of Medical Economics|September 1, 2023
Focal therapy versus radical prostatectomy and external beam radiotherapy as primary treatment options for non-metastatic prostate cancer: results of a cost-effectiveness analysisDeepika Reddy, Marieke van Son, Max Peters, et al.
European Urology Oncology|July 7, 2024
Patients' Preferences for Cytoreductive Treatments in Newly Diagnosed Metastatic Prostate Cancer: The IP5-MATTER StudyMartin J Connor, Mesfin Genie, Tim Dudderidge, et al.
European Urology Oncology|June 14, 2025
Combination Cytoreductive Surgery, Radiotherapy, or Ablation for De Novo Metastatic Prostate Cancer: The IP2-ATLANTA Internal Pilot, Phase 2, Randomised Controlled TrialMartin J Connor, Taimur T Shah, Johanna Sukumar, et al.
Prostate Cancer and Prostatic Diseases|May 2, 2021
Conventional radical versus focal treatment for localised prostate cancer: a propensity score weighted comparison of 6-year tumour controlMarieke J van Son, Max Peters, Deepika Reddy, et al.
Contemporary Clinical Trials|April 16, 2026
The Imperial Prostate 9 - Approaches To Long-term Active Surveillance: Regular MRI scans versus standard of care (IP9-ATLAS) randomised controlled trialArchana Gopalakrishnan, Alexander Light, Nikhil Mayor, et al.
Lancet (London, England)|February 14, 2021
Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programmeRuth E Langley, Duncan C Gilbert, Trinh Duong, et al.
BMJ Open|February 26, 2021
Additional Treatments to the Local tumour for metastatic prostate cancer-Assessment of Novel Treatment Algorithms (IP2-ATLANTA): protocol for a multicentre, phase II randomised controlled trialMartin John Connor, Taimur Tariq Shah, Katarzyna Smigielska, et al.
Pageof 4